9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed

Condition Peritoneal Carcinomatosis|Pseudomyxoma Peritonei|Peritoneal Mesothelioma Estimated Enrollment: 125 Age Group: Child, Adult, Senior Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Only|Time Perspective: Prospective Study ID Numbers: S-54350 Study First Received: June 8, 2012 Last Updated: July 28, 2016 Estimated Primary Completion Date: June 2018 Primary Outcome Measures: To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface. Sponsors and Collaborators: Universitaire Ziekenhuizen Leuven Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01617382...

Continue reading

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

Condition Non-small Cell Lung Cancer|Malignant Pleural Mesothelioma|Large Cell Neuroendocrine Carcinoma of the Lung Estimated Enrollment: 120 Age Group: 18 Years to 85 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label Study ID Numbers: AK-2015-LC-1 Study First Received: April 19, 2016 Last Updated: November 18, 2016 Estimated Primary Completion Date: April 2023 Primary Outcome Measures: Study Ia: Overall survival (OS)|Study Ib: Overall survival (OS)|Study II and III: Uptake of 68Ga-NOTA-AE105 in primary tumor lesion (dichotomized +/-)|Study Ia: Progression free survival (PFS)|Study Ib: Disease free survival (DFS) Sponsors and Collaborators: Rigshospitalet, Denmark Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02755675...

Continue reading

Clinical and Histopathologic Characteristics of BAP1 Mutations

Condition Malignant Pleural Mesothelioma (MPM)|Choroidal Nevus|Primary Uveal Melanoma (UM)|Metastatic Uveal Melanoma (UM)|Renal Cell Carcinoma|Cholangiocarcinoma Estimated Enrollment: 460 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: 12-235 Study First Received: January 18, 2013 Last Updated: January 27, 2017 Estimated Primary Completion Date: January 2018 Primary Outcome Measures: determine the prevalence of germline BAP1 mutations|prevalence of somatic BAP1 mutations in disease mesothelioma and metastatic uveal melanoma. Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center|United States Department of Defense Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01773655...

Continue reading

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Condition Pleural Mesothelioma Malignant Advanced|Peritoneal Mesothelioma Malignant Advanced|Non-squamous Non-small Cell Lung Carcinoma Stage IIIB/IV (NSCLC)|Metastatic Uveal Melanoma|Hepatocellular Carcinoma (HCC)|Glioma|Sarcomatoid Cancers Estimated Enrollment: 88 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: POLARIS2013-006 Study First Received: December 16, 2013 Last Updated: April 3, 2017 Estimated Primary Completion Date: August 2018 Primary Outcome Measures: Define initial estimates of efficacy, measured by RECIST 1.1 criteria for non-squamous NSCLC, advanced peritoneal mesothelioma, metastatic uveal melanoma, HCC, glioma and sarcomatoid cancers for ADI-PEG 20 in combination with pemetrexed and cisplatin.|Define initial estimates of efficacy, measured by...

Continue reading

A Study of LY3023414 in Participants With Advanced Cancer

Condition Advanced Cancer|Metastatic Cancer|Non-Hodgkin's Lymphoma|Metastatic Breast Cancer|Malignant Mesothelioma|Non-small Cell Lung Cancer Estimated Enrollment: 130 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 13517|I6A-MC-CBBA Study First Received: July 19, 2012 Last Updated: March 22, 2017 Estimated Primary Completion Date: March 4, 2018 Primary Outcome Measures: Recommended Phase 2 dose|Pharmacokinetics: Maximum concentration (Cmax)|Pharmacokinetics: Time of maximal concentration|Number of participants with tumor response|Potential of LY3023414 to inhibit CYP3A4-mediated metabolism Sponsors and Collaborators: Eli Lilly and Company Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01655225...

Continue reading

Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy

Condition Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Uterine Cancer|Mesotheliomas|Gastrointestinal Cancers|Cervical Cancer Estimated Enrollment: 200 Age Group: 18 Years to 75 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: HIPEC Study First Received: December 22, 2014 Last Updated: January 30, 2017 Estimated Primary Completion Date: January 2018 Primary Outcome Measures: measure treatment response to HIPEC and tumor debulking|Toxicity Monitoring Sponsors and Collaborators: Bay Area Gynecology Oncology Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02349958...

Continue reading

Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM

Condition Non Small Cell Lung Cancer (NSCLC)|Malignant Pleural Mesothelioma (MPM) Estimated Enrollment: 32 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 2014-53 Study First Received: September 11, 2015 Last Updated: September 18, 2015 Estimated Primary Completion Date: August 2018 Primary Outcome Measures: Phase IA : Treatment-related hematological toxicities (neutropenia) of grade 3-4 as assessed by CTCAE v4.0|Phase IB : Objective response rate according to RECIST1.1 for NSCLC and RECIST1.1 modified for MPM Sponsors and Collaborators: Assistance Publique Hopitaux De Marseille Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02555007...

Continue reading

MPM PDT Phase II Trial

Condition Epitheliod Malignant Pleural Mesothelioma Estimated Enrollment: 102 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Primary Purpose: Treatment Study ID Numbers: UPCC 14513 Study First Received: May 28, 2014 Last Updated: December 6, 2016 Estimated Primary Completion Date: May 2018 Primary Outcome Measures: Number of adverse events Sponsors and Collaborators: Abramson Cancer Center of the University of Pennsylvania Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02153229...

Continue reading

SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access

Condition Any Stage of Lung Cancer (Any Histotype)|Any Stage of Malignant Pleural Mesothelioma|Any Stage of Any Thymic Malignancy Estimated Enrollment: 3500 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: EORTC-1335-LCG-PBG Study First Received: August 7, 2014 Last Updated: January 17, 2017 Estimated Primary Completion Date: January 2019 Primary Outcome Measures: Number of patients with thoracic malignancy (lung cancer, MPM and thymic malignancies) screened and efficiently allocated to biomarker-driven clinical trials.|Number of patients for whom the description of the biomarkers and correlation to clinical/pathological characteristics can be performed.|Number of exploratory/future research projects developped Sponsors and Collaborators: European Organisation...

Continue reading

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Condition Medical Oncology Estimated Enrollment: 30 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 17631 Study First Received: November 30, 2015 Last Updated: April 12, 2017 Estimated Primary Completion Date: March 26, 2018 Primary Outcome Measures: Maximum tolerated dose (MTD)|Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability|Plasma concentrations of anetumab ravtansine (BAY 94-9343), pemetrexed and cisplatin|Tumor response evaluation following mRECIST criteria to determine the number of patients with CR, PR, SD or PD|Number of patients with a positive titer of anti-drug antibodies Sponsors...

Continue reading